EarningsNovo Nordisk Surges 24.9% in 30 Days After Q1 Beat, Bets on AI Partners Over In-House R&DSalvado•Jun 9, 2026
Biotech EquitiesNovo Nordisk's 24.9% Rally Bets on AI-Driven Pipeline Over In-House BiologySalvado•May 31, 2026
Pharma/Biotech StocksNovo Nordisk Jumps 24.9% in 30 Days as AI Drug Pipelines Win Market ConfidenceSalvado•May 27, 2026
Pharma Earnings & Stock PerformanceNovo Nordisk Surges 25% in 30 Days as Market Rewards AI-Driven R&D OverhaulSalvado•May 18, 2026
Pharma SectorNovo Nordisk Shares Surge 24.9% After Parkinson's AI Deal and Cell Therapy ExitSalvado•May 13, 2026
